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ExtEndEd rEport
H1N1 vaccination in Sjögren’s syndrome triggers 
polyclonal B cell activation and promotes 
autoantibody production
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ABSTRACT
Objectives Vaccination of patients with rheumatic 
disease has been reported to result in lower antibody 
titres than in healthy individuals. However, studies 
primarily include patients on immunosuppressive 
therapy. Here, we investigated the immune response 
of treatment-naïve patients diagnosed with primary 
Sjögren’s syndrome (pSS) to an H1n1 influenza vaccine.
Methods patients with Sjögren’s syndrome without 
immunomodulatory treatment and age-matched and 
gender-matched healthy controls were immunised 
with an H1n1 influenza vaccine and monitored for 
serological and cellular immune responses. Clinical 
symptoms were monitored with a standardised form. 
IgG class switch and plasma cell differentiation were 
induced in vitro in purified naïve B cells of untreated 
and hydroxychloroquine-treated patients and healthy 
controls. Gene expression was assessed by nanoString 
technology.
Results Surprisingly, treatment-naïve patients with 
Sjögren’s syndrome developed higher H1n1 IgG titres 
of greater avidity than healthy controls on vaccination. 
notably, off-target B cells were also triggered resulting in 
increased anti-EBV and autoantibody titres. Endosomal 
toll-like receptor activation of naïve B cells in vitro 
revealed a greater propensity of patient-derived cells to 
differentiate into plasmablasts and higher production 
of class switched IgG. the amplified plasma cell 
differentiation and class switch could be induced in 
cells from healthy donors by preincubation with type 1 
interferon, but was abolished in hydroxychloroquine-
treated patients and after in vitro exposure of naïve B 
cells to chloroquine.
Conclusions this comprehensive analysis of the 
immune response in autoimmune patients to exogenous 
stimulation identifies a mechanistic basis for the B cell 
hyperactivity in Sjögren’s syndrome, and suggests that 
caution is warranted when considering vaccination in 
non-treated autoimmune patients.
InTROduCTIOn
Infectious diseases are a major cause of morbidity 
and mortality in patients with systemic rheumatic 
diseases.1 2 Vaccination is one of the most effective 
measures to prevent infections; however, safety and 
efficacy need to be considered in the context of a 
dysregulated immune system. Studies of individuals 
with autoimmune rheumatic diseases indicate that 
patients develop reduced protective antibody titres 
on immunisation.3–5 However, many patients are 
treated with immunosuppressive drugs, which likely 
affect their response to vaccination. In addition, 
most reports focus on assessing vaccine efficacy by 
measuring seroconversion rates and production of 
neutralising antibodies, which leaves other poten-
tially important aspects of the immune response 
unexplored. The response of an autoimmune-bi-
ased immune system to stimuli such as vaccination 
or infections therefore remains unclear.
Due to early reports of high mortality among 
younger individuals during the H1N1 influenza 
pandemic,6 the Swedish government offered 
protective immunisations to all citizens. We used 
this opportunity to analyse the immune response 
to the vaccine of patients with primary Sjögren’s 
syndrome (pSS) without immunomodulatory 
treatment.
Here, we report that untreated patients with pSS 
respond to vaccination with enhanced antibody 
responses and, importantly, rising autoantibody 
titres. We find that naïve B cells from untreated 
patients readily differentiate into class-switched 
antibody-producing cells on endosomal toll-like 
receptor (TLR) stimulation. Furthermore, this 
hyper-reactive state is linked to proinflammatory 
cytokine exposure and upregulation of several 
intracellular signalling pathways including those 
downstream of TLR7 and TLR9 in patients with 
primary Sjögren’s syndrome.
MeThOdS
Detailed methods and study participant charac-
teristics are provided in the online supplementary 
materials.
Participants and vaccination procedure
Female patients with pSS fulfilling the American-Eu-
ropean consensus critera7 and positive for anti-Ro/
SSA and/or anti-La/SSB autoantibodies (n=14) 
and matched healthy controls (n=18) (supple-
mentary table S1) were vaccinated twice with the 
squalene-adjuvanted inactivated split-virion H1N1 
vaccine Pandemrix (GlaxoSmithKline, Brentford, 
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UK). Blood sampling and collection of clinical parameters was 
performed prior to, and 1 and 3 weeks after each vaccination.
In vitro class switch experiments were performed using blood 
samples from 14 untreated and 11 antimalarial drug-treated 
patients with Sjögren’s syndrome and 16 matched healthy 
controls (supplementary table S2). Cytokine stimulation and in 
vitro chloroquine treatment experiments were performed using 
cells from buffy coats of healthy blood donors.
The local Ethics Committee Stockholm North approved the 
study and all participants gave written informed consent.
Statistical analysis
Student’s t-test (normal distribution) or Mann-Whitney U-test 
(non-normal distribution) was used when comparing two 
groups, and Wilcoxon paired test when analysing paired data, 
all using Prism V.7 (GraphPad). Area under the curve (AUC) 
was calculated and analysed using R. Longitudinal variation of 
continuous parameters was analysed by quantile regression using 
Stata (StataCorp, College Station, Texas, USA).
ReSulTS
Vaccination induces higher specific and non-specific antibody 
responses in untreated patients with pSS
To assess the impact of vaccination in autoimmune individuals 
without interference from immune-targeting therapies, we moni-
tored untreated patients diagnosed with pSS during vaccination 
with an H1N1 influenza vaccine (Pandemrix) (figure 1A, supple-
mentary table S1).8–10 11 In contrast to previous reports,5 12–14 we 
observed markedly higher levels of H1N1 influenza-specific IgG 
antibodies in patients, mainly of the IgG1 subclass, compared 
with controls. Furthermore, H1N1 antibodies developed by the 
patients had higher avidity than those of controls (figure 1B-D, 
supplementary figure S1A). H1N1-specific IgM and IgA titres 
did not differ between the two groups, and haemagglutinin anti-
body titres, used as a measure of vaccine-induced protection 
and previously reported to be lower in patients with rheumatic 
disease,15 were comparable between the groups (supplementary 
figure S1B, C).
To further explore the impact of vaccine-induced immune acti-
vation on humoral responses in non-treated patients with pSS, 
we analysed the presence of antibodies to other influenza A and 
B strains. Interestingly, we observed that these antibody titres 
increased more in patients than in controls on A/H1N1 vacci-
nation (supplementary figure S1D). While this may be due to 
similarities between the H1N1 vaccine influenza strain and previ-
ously encountered viruses, it is however also possible that vacci-
nation reactivated the patients’ memory B cells in an unspecific 
manner. We therefore investigated antibody levels to the non-in-
fluenza pathogen Epstein-Barr virus (EBV), to which immunity 
is common and which has been implicated in pSS pathogenesis. 
Notably, antibody titres to EBV increased in patients following 
vaccination, but not in controls (figure 1E). Next, we analysed 
whether vaccination had an impact also on autoreactive memory 
B cells and found that autoantibody titres to the Sjögren’s 
syndrome-associated autoantigens Ro/SSA (Ro52 and Ro60) and 
La/SSB16 17 indeed increased significantly during the course of 
vaccination (figure 1F). No new autoantibody specificities were 
noted (data not shown), and no expansion or dominance of a 
specific B cell clonotype was observed in patients compared 
with controls, as analysed by VH-spectratyping (supplementary 
figure S2). Consistent with the elevated specific IgG titres and 
polyclonal B cell activation, higher frequencies of circulating 
CD19dimCD138+ plasmablasts and IgG-secreting B cells were 
detected in patients following vaccination (figure 1G and H 
supplementary figure S3).
Previous studies have indicated that vaccination does not 
exacerbate disease in patients with autoimmune rheumatic 
diseases.5 14 Considering a potentially stronger immune reac-
tion in non-treated patients, we monitored common clinical 
signs of disease activity, such as fever, fatigue, myalgia and 
arthralgia, by a standardised form filled out by the partici-
pants at each visit throughout the study. These parameters 
are now part of the Sjögren’s syndrome disease activity scores 
European League Against Rheumatism Sjögren’s Syndrome 
Patient Reported Index (ESSPRI) and European League Against 
Rheumatism Sjögren’s Syndrome Disease Activity Index 
(ESSDAI),18 19 which were not yet established at the time of 
the study, but confirms their relevance. Notably, fever, fatigue, 
myalgia and arthralgia also constitute common adverse reac-
tions to vaccination, and the frequencies of patients and controls 
reporting such symptoms followed similar trends during the 
vaccination period (figure 2A-D supplementary figure S4).
In all, our data demonstrate that immunisation with an H1N1 
influenza vaccine not only induces higher specific antibody 
responses in untreated autoimmune patients with pSS, but also 
drives polyclonal B cell activation, including that of autoreactive 
cells, leading to an increase in autoantibody titres.
differential peripheral responses to vaccination between 
patients with pSS and controls
To acquire a more comprehensive understanding of the response 
triggered by vaccination in untreated autoimmune patients beyond 
antibody production, we analysed circulating B cell and T cell 
populations as well as serum levels of cytokines. There were no 
major differences in lymphocyte populations between patients 
and controls before vaccination, except for a lower frequency of 
circulating memory B cells and an increased proportion of naïve 
B cells in patients, confirming previous studies.20 Vaccination 
did not induce further differences between patients and controls 
in either B cell counts or frequencies of B cell subsets. However, 
B cells from patients expressed significantly more HLA-DR as a 
sign of activation 3 weeks after both the vaccination and the boost 
(figure 3A supplementary figure 5). We did not detect any notable 
difference in either T cell numbers or activation status between 
groups apart from a decreased CD62L expression on CD4+ T cells 
after the initial vaccination (supplementary figure S6A-C). None of 
the hallmark T-helper lineage cytokines interferon-γ (IFN-γ), inter-
leukin (IL)-4 or IL-17 were differently expressed (supplementary 
figure S6D).
Analysis of cytokine expression showed high basal serum levels 
of the proinflammatory cytokines IFN-α, BAFF and TNF-α in 
untreated patients with pSS (figure 3B), as previously reported.9 21–23 
These levels remained significantly elevated in patients throughout 
the study, or were even further induced. By contrast, the B cell 
activating cytokines IL-10, IL-6 and IL-7 were detected at compa-
rable serum levels in patients and controls before vaccination, 
but were significantly more induced in patients on immunisation 
(figure 3C), suggesting that they might be responsible, at least in 
part, for the increased antibody production and B cell activation 
observed in patients after vaccination.24–27
naïve B cells from patients with pSS more readily 
differentiate into Cd19dimCd138+ plasmablasts after 
endosomal TlR stimulation
In view of the increase in IgG titres following vaccination, we 
investigated the possibility that B cells from untreated patients 
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with pSS are more prone to differentiate into antibody-pro-
ducing cells in response to immune triggering. Therefore, we 
analysed plasma cell differentiation and immunoglobulin (Ig) 
class switch in vitro of naïve CD19+IgD+ B cells isolated from 
untreated patients with pSS and healthy donors (supplementary 
table S2). Anti-CD40, BAFF as well as TLR7 (imiquimod) and 
TLR9 (CpG) agonists have previously been described to drive 
these processes28–35 and were thus selected for in vitro differ-
entiation assays. After an initial screening of IL-4, IL-10 and 
IL-21 (supplementary figure S7A), supplementation with IL-10 
was chosen for all cultures as this cytokine promoted the most 
efficient plasma cell differentiation and class switch.24 Interest-
ingly, we observed that a higher number of CD19dimCD138+ 
plasmablasts developed in cultures of pSS patient-derived cells 
compared with controls on TLR7 and TLR9 stimulation, and 
higher levels of IgM and IgG were detected in supernatants 
(figure 4A, supplementary figure S7B). By contrast, anti-CD40 
and BAFF stimulation did not differentially affect Ig class switch 
or plasma cell differentiation between patients and controls.
To understand why endosomal TLR ligands induced plasma 
cell differentiation and class switch more effectively in naïve 
B cells isolated from untreated patients with pSS, we investi-
gated gene expression profiles before and after in vitro stimula-
tion, using NanoString nCounter multiplex expression profiling 
(supplementary figure S8). For the analysis, genes were grouped 
into functional clusters based on GeneOntology and Ingenuity 
Figure 1 H1N1 vaccination induces higher specific IgG response and polyclonal activation of B cells in Sjögren’s syndrome. (A) Untreated patients 
with primary Sjögren’s syndrome (pSS, n=14) and healthy controls (HC, n=18) were subjected to H1N1 vaccination and boost, and followed by blood 
sampling five times during 42 days. (B) H1N1-specific IgG levels in pSS and HC measured by ELISA. (C) IgG1 subclass H1N1-specific antibodies in pSS 
and HC measured by ELISA. (D) Avidity of anti-H1N1-specific IgG in pSS and HC, measured by an ELISA-based 8 M urea competition assay. (E) Anti-
EBV-VCA IgG levels in pSS and HC measured by ELISA. (F) Ro52/SSA, Ro60/SSA and La/SSB autoantibody levels in pSS measured by ELISA. (G) Live 
CD14-CD3-CD19dimCD138+CD27+ plasmablasts in pSS and HC assessed by flow cytometry. (H) IgG producing cells detected by ELISPOT. Representative 
wells from day 42 are shown in the right panel. Numbers indicate spots/106 peripheral blood mononuclear cell (PBMC). Data are presented as 
mean±SD. AUC, area under the curve; QR, quantile regression. *p<0.05, **p<0.01 (Mann-Whitney U test, Student’s t-test, Wilcoxon signed-rank test).
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gene sets (supplementary table S3). Gene expression profiling 
revealed prominent differences between the naïve, unstim-
ulated B cells derived from patients and controls: immune 
genes belonging to a broad spectrum of clusters, including the 
type I IFN pathway, antigen presentation, B cell development 
and endosomal TLR signalling, were markedly upregulated in 
B cells from patients (figure 4B,C, supplementary figure S9). 
After in vitro cell stimulation, the initial gene expression pattern 
differences diminished, except for gene sets pertaining to plasma 
cells, reflecting the enhanced differentiation process (supple-
mentary figure S10, table S4).
Taken together, our findings show that naïve B cells from 
patients with pSS are in a state of hyper-responsiveness, char-
acterised by the overexpression of a variety of immune-related 
genes, including those downstream of endosomal TLR signal-
ling, and an enhanced capacity to undergo class switch and 
Figure 2 Disease activity on vaccination. Information on experienced symptoms of Sjögren’s syndrome during the preceding week was collected. 
Significant differences were observed after the second vaccination. (A) Fever. (B) Fatigue. (C) Myalgia. (D) Arthralgia. Data are presented as 
percentage.
Figure 3 B cell activation and induction of proinflammatory cytokines on vaccination in patients with pSS. (A) Freshly isolated PBMC from patients 
with pSS and healthy controls were analysed by flow cytometry at each blood sampling time point during the vaccination protocol. Representative 
dot or histogram plots (left) and quantification graphs (right) are shown for each analysis. Numbers adjacent to outlined gates indicate percentage 
positive cells. (B, C) Cytokine concentrations in serum samples analysed by a Luminex assay (tumour necrosis factor-α (TNF-α), interleukin (IL)-10, 
IL-6, IL-7) or ELISA (interferon-α (IFN-α), B cell activating factor (BAFF)). Data are presented as mean±SD. AUC, area under the curve; QR, quantile 
regression. *p<0.05, **p<0.01, ***p<0.001 (Mann-Whitney U test).
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plasma cell differentiation when triggered by endosomal TLR 
ligands.
IFn-α sensitises B cells and promotes Cd19dimCd138+ 
plasmablast differentiation on TlR stimulation
We next set out to understand the mechanisms underlying the 
hyper-responsiveness of B cells from untreated patients with 
pSS. Based on our observations that these patients had elevated 
serum levels of IFN-α (figure 3B) and that genes involved in 
downstream type I IFN pathways were upregulated in cells 
isolated from untreated patients (figure 4B), combined with the 
known role of IFN-α in promoting class switch,36 37 we hypoth-
esised that IFN-α might be responsible for the hyper-reactive 
state of B cells in untreated patients with pSS. Therefore, to 
Figure 4 Toll-like receptor (TLR)-induced plasma cell differentiation and class switch are enhanced in naïve B cells from patients with 
primary Sjögren’s syndrome (pSS). (A) fluorescence-activated cell sorter (FACS) sorted naïve CD19+IgD+ B cells from freshly isolated peripheral blood 
mononuclear cell of untreated patients with pSS (n=14) and healthy controls (HC) (n=16) were cultured for 8 days under plasmablast and class switch 
promoting conditions with anti-CD40, BAFF, CpG or imiquimod (Imiq). At day 8, the frequency of CD19dimCD138+ plasmablasts and IgM and IgG 
concentrations in supernatants were assessed by flow cytometry and ELISA. Data represent pooled data from 10 independent experiments. (B) mRNA 
was extracted from the naïve B cells at day 0 and gene expression analysed by NanoString. Heat map illustrates expression in patients with pSS 
and HC organised by Ingenuity pathways and Gene ontology analysis using average Z scores. The 14 most differentially regulated gene clusters are 
displayed in order of mean fold change of the top 10 upregulated genes in each cluster. (C) Network analysis of differentially expressed genes show 
that pSS-related genes cluster into the pathways type I interferon (IFN) pathway, antigen presentation and BCR signalling and B cell development. 
Symbols according to Ingenuity. Brighter red indicates higher upregulation in pSS compared with HC. Data are presented as mean±SD. *p<0.05, 
**p<0.01, ***p<0.001 (Mann-Whitney U test). IL, interleukin.
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directly assess whether IFN-α could sensitise B cells to subse-
quent endosomal TLR stimulation, we incubated naïve B cells 
isolated from healthy donors with IFN-α before culturing them 
under plasmablast-differentiating conditions. Strikingly, this 
was enough to recapitulate the enhanced differentiation and 
class-switch capacity that we had previously observed in B cells 
isolated from untreated patients with pSS (figure 5A). Gene 
expression analysis of cells primed with IFN-α revealed upreg-
ulation of genes related to type I IFN pathways and endosomal 
TLR signalling (figure 5B, supplementary table S4), which we 
had also found to be upregulated in cells from untreated patients 
with pSS.
hydroxychloroquine treatment abolishes B cell hyper-
responsiveness to TlR stimulation in patients with pSS
Initially discovered as an antimalarial drug, hydroxycholo-
roquine (HCQ) is commonly used for treatment of pSS and 
systemic lupus erythematosus (SLE).38 39 HCQ acts by inhib-
iting endosomal TLR signalling, and was recently reported to 
decrease both IFN-α production in SLE40 41 and the IFN signa-
ture in patients with pSS.42 Since priming B cells with IFN-α 
resulted in enhanced B cell differentiation and class switch after 
TLR stimulation in vitro, we investigated whether HCQ treat-
ment would decrease the B cell hyper-responsiveness in patients 
with pSS. So far, no direct effect of chloroquine on B cells has 
been established. We therefore first analysed the effect of chlo-
roquine on B cell class switch. CD19+IgD+ B cells from healthy 
donors were treated with chloroquine in vitro, simultaneously as 
class switch was induced by TLR7 and TLR9 stimulation. Addi-
tion of chloroquine at pharmacologically relevant concentrations 
led to significantly less differentiation of CD19dimCD138+ cells, 
class switch and IgM and IgG production (figure 6A). Strikingly, 
we further found that naïve B cells isolated from HCQ-treated 
patients with pSS were significantly less prone to differentiate 
into CD19dimCD138+ plasmablasts and undergo class switch 
on TLR9 stimulation (CpG) than cells of untreated patients 
(figure 6B). A similar trend was observed for TLR7-stimulated 
cells. Analysis of gene expression revealed that HCQ treatment 
of patients with pSS abolished the upregulation of immune genes 
otherwise found in B cells from untreated patients (figure 6C,D, 
supplementary figure S11, table S4). This suggests that HCQ 
treatment may act directly on naïve B cells, and reverses the 
enhanced capacity of B cells from patients with pSS to differen-
tiate into plasma cells on TLR stimulation in vitro by preventing 
these cells to become hyper-responsive in the first place.
Altogether, our findings demonstrate that B cells from healthy 
donors can become hyper-responsive to TLR stimulation on 
exposure to IFN-α and that, conversely, the increased reactive 
state of B cells from patients with pSS can be reversed by HCQ 
treatment.
Figure 5 Interferon-α (IFN-α) preactivation recapitulates a Sjögren-like B cell phenotype. (A) fluorescence-activated cell sorter (FACS) 
sorted CD19+IgD+ cells from healthy donors (n=5) were cultured with IFN-α for 18 hours prior to stimulation with CpG+interleukin (IL)-10, 
imiquimod (Imiq)+IL-10, IL-10 alone or medium. Frequencies of CD19dimCD138+ plasmablasts, and total IgM and IgG concentrations in supernatants 
were analysed at day 8. Data represent pooled data from 3 independent experiments. (B) Gene expression of cells was measured at day 0 and 8 
by NanoString. Graph depicts values of mean fold change of clusters 1–14 in cells cultured for 8 days and normalised to expression day 0. Data are 
presented as mean±SD. *p<0.05, **p<0.01, ***p<0.001 (Mann-Whitney U test).
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dISCuSSIOn
Assessing the efficacy of vaccines in patients with autoimmune 
rheumatic diseases is crucial to provide adequate recommenda-
tions for clinical practice. However, these types of studies may 
miss potential aspects of how a dysregulated immune system 
reacts to an immune trigger such as a vaccine, especially since 
they often include patients treated with immunomodulatory 
drugs. Here, we studied the immune response of treatment-naïve 
Figure 6 The B cell hyper-reactivity in patients with Sjögren’s syndrome is abrogated by hydroxychloroquine (HCQ) treatment. (A) Class switch 
was induced by imiquimod (Imiq)+interleukin (IL)-10 or CpG+IL-10 in freshly prepared CD19+IgD+ B cells from buffy coats (n=5) with or without 
chloroquine in physiological concentrations (1 μg/mL). At day 8, cells were analysed for CD138+CD19dim expression by flow cytometry, and IgM and 
IgG concentrations were determined in supernatants. Chloroquine significantly reduced class switch in both Imiq-treated and CpG-treated wells, 
without affecting cells in IL-10 and untreated wells. Data represent pooled data from 3 independent experiments. (B) FACS sorted CD19+IgD+ B cells 
from untreated (n=14) and HCQ or chloroquine treated (n=11) patients with pSS and healthy controls (HC) (n=16) were subjected to class switch 
induction in vitro by Imiq+IL-10 or CpG+IL-10. Data represent pooled data from 18 independent experiments. (C) Heat map of gene expression 
comparing naïve IgD+ B cells from untreated and HCQ-treated patient with pSS and HC. (D) Mean fold change of clusters 1–14 in cells cultured for 
8 days compared with day 0. Gene expression was measured by NanoString and normalised to expression day 0. Data are presented as mean±SD. 
*p<0.05, **p<0.01, ***p<0.001 (Mann-Whitney U test).
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autoimmune patients diagnosed with pSS to an H1N1 influenza 
vaccine. In contrast to previous studies reporting less vigorous 
immune responses to vaccination in patients with autoimmune 
rheumatic disease,5 12 13 we found that untreated patients with 
pSS developed higher levels of vaccine-specific IgG antibodies 
than matched controls. Impaired responses to vaccination in 
autoimmune patients may therefore relate rather to ongoing 
immunosuppressive therapy than to the immune system being 
inherently less able to mount protective antibody responses.
Interestingly, we observed that untreated patients with pSS 
responded to immunisation with higher vaccine-specific anti-
body titres than matched controls, and with a general increase 
in non-specific antibody and autoantibody levels, and higher 
numbers of circulating CD19dimCD138+ plasmablasts. We 
further found that B cells isolated from untreated patients were 
more prone to differentiate into class-switched antibody-pro-
ducing plasma cells than cells from controls when stimulated 
in vitro with TLR7 and TLR9 agonists, and that they overex-
pressed a broad panel of immune-related genes compared with 
controls already prior to stimulation including those in the 
signalling pathways downstream of TLR7 and TLR9. These 
findings suggest that B cells from untreated patients with pSS 
are in a state of hyper-responsiveness, in particular to endo-
somal TLR stimulation. Interestingly, a recent study showed 
that TLR7 was required for optimal antibody production after 
immunisation with the 2009 pandemic split vaccine (Sanofi 
Pasteur, Swiftwater, Pennsylvania, USA) in mice,43 and that this 
was likely due to TLR7 recognition of viral RNA present in the 
split vaccine. It is therefore possible that RNA present in the 
split-virus Pandemrix vaccine used in our study may contribute 
to the increased plasma cell differentiation and antibody produc-
tion detected in patients by stimulating B cell endosomal TLRs. 
We also observed an increased production of the B cell-pro-
moting cytokine IL-10 following immunisation in patients with 
pSS  compared with controls, suggesting that additional factors 
besides TLR stimulation of B cells may contribute to enhanced 
humoral responses in patients with pSS. Altogether, in view of 
our findings showing that B cells from untreated patients with 
pSS are especially hyper-responsive to endosomal TLR triggers, 
caution may be warranted when immunising these patients with 
vaccines containing TLR agonists—whether added as adjuvants 
or naturally present in whole or split-virus preparations. Of 
note, the same patients would presumably respond to vaccina-
tion and to natural infections with a broad increase in specific 
and non-specific antibody responses. An evolutionary advantage 
of the capacity to respond with high levels of specific antibodies 
may be the ability to survive infections, and could explain the 
persistence of autoimmune-associated alleles within our gene 
pool. The delicate balance is illustrated by the fact that despite 
the markedly increased B cell responses observed in patients, we 
noted no significant differences between patients and controls 
with regard to the recorded clinical parameters fever, fatigue, 
myalgia and arthralgia. These manifestations represent common 
symptoms of both Sjögren’s syndrome and adverse reactions to 
vaccination,8 10 44 and similar frequencies of affected individuals 
was observed after vaccination.
Further analysis of the mechanism underlying B cell hyper-re-
sponsiveness in untreated patients with pSS revealed a major 
role for type I IFN. Indeed, the phenotype could be recapitu-
lated by priming B cells from healthy donors with IFN-α and 
was abolished by HCQ treatment in patients with pSS. HCQ 
has been reported to inhibit IFN-α production by plasmacytoid 
dendritic cells in SLE,40 as well as decrease the IFN signature 
in patients with pSS,42 and may therefore exert its therapeutic 
effect in pSS and SLE at least partly by suppressing TLR-induced 
IFN-α production and IFN-α-induced B-cell hyper-responsive-
ness. Such a mechanism may underlie the decrease in both IgM 
and IgG titres that were previously reported in patients with pSS 
receiving HCQ treatment.38 Clinical trials of HCQ in pSS on the 
other hand have not met primary end points.45 46 However, both 
inclusion criteria and primary outcomes analysed differed from 
the present study and they are therefore not directly comparable.
In all, our findings reveal that untreated patients with pSS 
respond to immunisation with increased antibody responses, 
that this effect is due to a hyper-responsiveness of B cells to 
endosomal TLR stimulation, and that this phenotype is, in turn, 
is related to the type I IFN milieu present in these patients.
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